MetaCap

Theriva Biologics (TOVX) vs Tempest Therapeutics (TPST)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Theriva Biologics (TOVX) has outperformed Tempest Therapeutics (TPST) over the past year, losing 45.5% versus a loss of 91.8%. Over five years, TPST leads with a -99.8% price change compared with -99.9% for TOVX. Tempest Therapeutics is the larger company by market cap ($5.7 million vs $5.5 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

TOVX-45.45%TPST-91.80%
+95%-3%-101%
Nov 21, 20251 yearNov 20, 2026
TOVX-99.87%TPST-99.79%
+25%-40%-106%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

TOVX versus TPST key metrics
MetricTOVXTPST
Share price$0.12$0.287
Market cap$5.51M$5.74M
1-day change-6.25%-6.18%
YTD return-42.86%-90.00%
1-year return-45.45%-91.80%
5-year return-99.86%-99.77%
P/E ratio (TTM)0.10—
EPS (TTM)$1.15$-3.16
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-23.74M$-26.26M
52-week high$0.49$4.22
52-week low$0.12$0.28
Distance from 52-week high-75.51%-93.20%
Analyst consensusnonestrong_buy
Avg. price target upside+1983.33%+2339.02%
Average volume2.02M2.56M
Shares outstanding45.89M20.00M
Employees154
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • TOVX has outperformed TPST by 46.3 percentage points over the past year.

About Theriva Biologics

TOVX stock →

Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. Its lead product candidate, VCN-01 (zabilugene almadenorepvec), a clinical stage oncolytic human adenovirus that is in Phase 1 clinical trials and Phase 2 VIRAGE trial for patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian cancer, colorectal cancer, and retinoblastoma.

Health Care · Biotechnology: Pharmaceutical Preparations · 15 employees

About Tempest Therapeutics

TPST stock →

Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers.

Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees

TOVX vs TPST FAQ

Which is bigger, Theriva Biologics or Tempest Therapeutics?

Tempest Therapeutics (TPST) is larger, with a market capitalization of $5.74M compared with $5.51M for Theriva Biologics (TOVX).

Which stock has performed better over the past year, TOVX or TPST?

TOVX returned -45.45% over the past 12 months, compared with -91.80% for TPST (price return, excluding dividends). Past performance does not predict future results.

Are Theriva Biologics and Tempest Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons